The Effect of Adalimumab on the Bone Microstructure in Crohn's Disease (CD) Patients

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01012570

Enrollment

Registered

2009-11-13

Start date

2009-08-31

Completion date

Unknown

Last updated

2014-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's Disease

Brief summary

The investigators will study the effect of Adalimumab on the bone microstructure. * Trial with medicinal product

Interventions

DRUGApplication of Adalimumab

Adalimumab will be applied according to manufacture's instruction and official guidelines.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* CDAI \> 220 und \< 450 * Biologika naiv * CD seit \> 6 Monaten

Exclusion criteria

* other TNF-Blocker * Steroids \> 40 mg * Malignoma in der Anamnesis

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026